Empress Therapeutics Appoints Dawn Thompson, Ph.D., Senior Vice President, Head of Platform Development
Empress Therapeutics Appoints Dawn Thompson, Ph.D., Senior Vice President, Head of Platform Development
08/16/23, 12:35 PM
Location
cambridge
Industry
biotechnology
Position
head of platform development
Empress Therapeutics, a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced that Dawn Thompson, Ph.D., has been appointed Senior Vice President, Head of Platform Development. With more than 20 years of experience leading cross-functional teams and building technology platforms at early-stage companies, Dr. Thompson will focus at Empress on platform innovation, adding new workflows and advanced genomics capabilities as well as efficiency and scale to all existing functions.
Company Info
Location
cambridge, maryland, united states
Additional Info
Founded by Flagship Pioneering in 2020, Empress Therapeutics generates good medicines, fast, by starting with chemistry inside the human body. The Empress Chemilogics(TM) platform uses novel insights that connect the lines of code in DNA with drug-like chemistry made in the human body to create first- or best-in-class oral medicines for a broad range of diseases quickly, predictably, and cost-effectively.